Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2239-2248

  Das, Kakoli ^a   Leong, David Tai ^a   Gupta, Anurag ^a   Shen, Liang ^a   Putti, Thomas ^a   Stein, Gary S ^b   van Wijnen, Andre J ^a,b   Salto Tellez, Manuel ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; CerbB2; Oestrogen receptor; Progesterone receptor; Runx2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; CYTOPLASM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR GROWTH; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 68749118305     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.021     Document Type: Article

References (50)

1. Henderson B.E., and Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 21 (2000) 427-433
2. Deroo B.J., and Korach K.S. Estrogen receptors and human disease. J Clin Invest 116 (2006) 561-570
3. Mueller S.O., and Korach K.S. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knock out mice. Curr Opin Pharmacol 1 (2001) 613-619
4. Herynk M.H., and Fuqua S.A. Estrogen receptor mutations in human disease. Endocr Rev 25 (2004) 869-898
5. Gao X., and Nawaz Z. Progesterone receptors-animal models and cell signaling in breast cancer: role of steroid receptor co-activators and co-repressors of progesterone receptors in breast cancer. Breast Cancer Res 4 (2002) 182-186
6. Conneely O.M., and Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 65 (2000) 571-577
7. Fuqua S.A.W., Cui Y., Lee A.V., and Osborne C.K. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol 23 (2005) 931-932
8. Giangrande P.H., Pollio G., and McDonnell D.P. Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J Biol Chem 272 (1997) 32889-32900
9. Clark G.M. In: Harris J.L.M., Morrow M., and Hellman S. (Eds). Diseases of the breast (1996), Lippincott-Raven, Philadephia 461-485
10. Honig S. In: Harris J.L.M., Morrow M., and Hellman S. (Eds). Diseases of the breast (1996), Lippincott-Raven, Philadelphia 461-485
11. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
12. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 (2001) 165-176
13. Kingsley L.A., Fournier P.G., Chirgwin J.M., and Guise T.A. Molecular biology of bone metastasis. Mol Cancer Ther 6 (2007) 2609-2617
14. Pratap J., Lian J.B., Javed A., et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25 4 (2006) 589-600 [Review]
15. Kakonen S.M., Selander K.S., Chirgwin J.M., et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277 (2002) 24571-24578
16. Bendre M.S., Margulies A.G., Walser B., et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65 (2005) 11001-11009
17. van Wijnen A.J., Stein G.S., Gergen J.P., et al. Nomenclature for runt-related (RUNX) proteins. Oncogene 23 (2004) 4209-4210
18. Barnes G.L., Hebert K.E., Kamal M., et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64 (2004) 4506-4513
19. Barnes G.L., Javed A., Waller S.M., et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63 (2003) 2631-2637
20. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 96 (2005) 484-489
21. Pratap J., Javed A., Languino L.R., et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25 (2005) 8581-8591
22. Javed A., Barnes G.L., Pratap J., et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102 (2005) 1454-1459
23. Coffman J.A. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 27 (2003) 315-324
24. Lian J.B., Javed A., Zaidi S.K., et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14 (2004) 1-41 [Review]
25. Valliant F., Blyth K., Terry A., et al. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene 18 (1999) 7124-7134
26. Brubaker K.D., Vessella R.L., Brown L.G., and Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56 (2003) 13-22
27. Nathan S.S., Pereira B.P., Zhou Y.F., et al. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36 1 (2009) 153-158
28. Galindo M., Pratap J., Young D.W., et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related anti-proliferative function in osteoblasts. J Biol Chem 280 (2005) 20274-20285
29. Pratap J., Galindo M., Zaidi S.K., et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 63 (2003) 5357-5362
30. Teplyuk N.M., Galindo M., Teplyuk V.I., et al. Runx2 regulates G-protein coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem 283 41 (2008) 27585-27597
31. Inman C.K., and Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278 (2003) 48684-48689
32. Inman C.K., Li N., and Shore P. Oct-1 counteracts auto inhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 25 (2005) 3182-3193
33. Viereck V., Siggelkow H., Tauber S., Raddatz D., Schutze N., and Hufner M. Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 86 (2002) 348-356
34. Drissi H., Pouliot A., Koolloos C., et al. 1, 25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274 2 (2002) 323-333
35. McCarthy T.L., Ji C., Chen Y., Kim K., and Centrella M. Time and dose-related interactions between glucocorticoid and cyclic adenosine 3′, 5′-monophosphate on CCAAT/enhancer binding protein-dependent insulin-like growth factor I expression by osteoblasts. Endocrinology 141 (2000) 127-137
36. Bijlsma J.W. Can we use steroid hormones to immunomodulate rheumatic diseases? Rheumatoid arthritis as an example. Ann NY Acad Sci 876 (1999) 366-376
37. Nishimura J., and Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 18 (2000) 350-352
38. Chang D.J., Ji C., Kim K.K., Casinghino S., McCarthy T.L., and Centrella M. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 273 (1998) 4892-4896
39. Mc Carthy T.L., Chang W.Z., Liu Y., and Centrella M. Runx2 integrates estrogen activity in osteoblasts. J Biol Chem 278 (2003) 43121-43129
40. Das K., Mohd Omar M.F., Ong C.W., et al. TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology 40 (2008) 441-449
41. Breast. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. (2002), Springer, New York, NY 171-180
42. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
43. Ito K., Liu Q., Salto-Tellez M., et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65 (2005) 7743-7750
44. Zhang D., Salto-Tellez M., Putti T.C., Do E., and Koay E.S. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16 1 (2003) 79-84
45. Plant A., Samuels A., Perry M.J., Colley S., Gibson R., and Tobias J.H. Estrogen-induced osteogenesis in mice is associated with the appearance of Cbfa1-expressing bone marrow cells. J Cell Biochem 84 (2002) 285-294
46. Taranta A., Brama M., Teti A., et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
47. Lau Q.C., Raja E., Salto-Tellez M., et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66 (2006) 6512-6520
48. Ito K., Lim A.C., Salto-Tellez M., et al. RUNX3 attenuates beta-Catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14 (2008) 226-237
49. Pockwinse S.M., Rajgopal A., Young D.W., et al. Microtubule-dependent nuclear-cytoplasmic shuttling of Runx2. J Cell Physiol 206 (2006) 354-362
50. Khalid O., Baniwal S.K., Purcell D.J., et al. Modulation of Runx2 activity by estrogen receptor {alpha}: implications for osteoporosis and breast cancer. Endocrinology 149 (2008) 5984-5995